☆ 4.7 Editorial Material

Risk of Total Events With Icosapent Ethyl Can We Reduce It?

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

Get Full Text
Add to Collection

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 73, Issue 22, Pages 2803-2805

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2019.03.492

Keywords

clinical trial; icosapent ethyl; recurrent events

Categories

Cardiac & Cardiovascular Systems

Funding

  1. Pfizer
  2. Amarin, Inc.
  3. Novo Nordisk
  4. Boehringer Ingelheim
  5. Regeneron
  6. AstraZeneca

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.